Genome-Based Discovery of Novel CpG Biomarkers for Early Diagnosis and Prognosis of Leukemia
CSEF · 2017 Biochemistry/ Molecular Biology Honorable_mention Award
Overview
Objectives/Goals The goals of this project is to a)identify and validate novel CpG biomarkers for early diagnosis and prognosis of leukemia; b) Develop a low-cost, non-invasive, rapid screening method for clinical leukemia diagnosis Methods/Materials The blood samples from leukemia patients and normal individuals were from UCSD. Reagents for DNA extraction, bisulfite conversion, PCR and sequencing were commercially available. Comprehensive analysis of genome-wide methylation data was performed with a customized software bis-Readmapper, followed by data classification with nearest shrunken centroids classifiers. The identified novel CpG biomarkers were further validated by machine learning and computational analysis for early diagnosis of leukemia. For prognostic analysis, I developed a semi-supervised approach with selected CpG biomarkers for prediction of five-year overall survival of leukemia patients. Results My results can be summarized as the followings 1)First-ever discovered and validated 10 novel CpG biomarkers, which enabled a CpG methylation based methodology for early leukemia diagnosis with more than 97% accuracy. 2)Provided proof-of-concept results of methylation specific PCR (MPCR) as a low-cost, rapid leukemia screening method in clinical settings 3) Developed methylation-based survival classifiers for prognostic prediction 4) Identified 10 CpG controlled genes critical for early cancer development Conclusions/Discussion This project has demonstrated the feasibility of using CpG methylation signatures for early leukemia diagnosis and prognosis. My study has significant implications in the current clinical diagnosis. First, the CpG methylation offers a platform for early cancer diagnosis, which can capture the biological state of a cell much earlier than the current morphology based approach. Second, the CpG methylation exhibits excellent accuracy and reproducibility. Third, the CpG biomarker detection utilizes blood samples with non-invasive procedures. Fourth, my low-cost MPCR method can be widely used for early cancer screening. In combination of circulating tumor DNA and liquid biopsy, this CpG methylation based technology can be potentially applicable to many different cancer types, with broader impacts in the field.
Summary statement
This project has demostrated a reliable and practical method for early cancer diagnosis and prognosis with newly identified CpG biomarkers through genome-based study
Help received
My supervisor provided lab reagents, instruments and training. I independently initiated my ideas, performed experiments, analyzed the data and wrote my research report.
Awards (1)
- Honorable Mention
Competition history
- CSEF 2017
Resources
Related projects
ISEF · 2017
Cytosine to Thymine: Unveiling Cancer's Achilles Heel via a Genome-wide Discovery of CpG Methylation Signatures
CSEF · 2018
iDetect: A Machine Learning Algorithm for Non-Invasive Cancer Diagnosis through Epigenetic Biomarker Identification
ISEF · 2019
Precision Care for Leukemia: Discovery of Novel Therapeutics for High-Risk ALL via Epigenetic and Computational Transcriptome Profiling
CSEF · 2014
Targeted Cancer Therapy and Diagnosis: Analyzing miRNA Expression Signatures & Interactions for Glioblastoma Progression
CSEF · 2018
A Precision Medicine Approach: Epigenetic Inhibitors Induce Highly-Specific Apoptosis in High Risk Acute Leukemia
CYSF · 2025
How can specific DNA methylation patterns enhance the early detection of leukemia?
CSEF · 2015
A Computer-Based Integrated Analysis of Genomic Signatures in Ovarian Cancer
ISEF · 2018
A Precision Medicine Approach to Cancer: Epigenetic Inhibitors Induce Highly-Specific Apoptosis in High Risk Acute Lymphoblastic Leukemia
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects